Inventor · disambiguated record
Christopher Ronald Smith
Also filed as: SMITH CHRISTOPHER · SMITH CHRISTOPHER R · SMITH CHRISTOPHER RONALD
30 granted patents·28 pending applications·165 citations·filing 1994–2025
96Inventor score
Files withMIRATI THERAPEUTICS INC32TAKEDA PHARMACEUTICALS CO5PFIZER4TAKEDA PHARMACEUTICAL4RHONE POULENC RORER LTD3
Top patents by PatentIndex Score
58 records- 0197US10689377B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Jun 23, 2020·16 cites·57 claims
- 0296US11453683B1KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·13 cites·84 claims
- 0392US12421253B2Tetrahydropyridopyrimidine pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·1 cites·29 claims
- 0492US11964989B2KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·2 cites·19 claims
- 0592US8440689B2Fused heteroaromatic pyrrolidinonesARIKAWA YASUYOSHI·Filed 2010·Granted May 14, 2013·23 cites·28 claims
- 0691US10647715B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted May 12, 2020·10 cites·9 claims
- 0789US11999753B2Tetrahydropyridopyrimidine pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jun 4, 2024·1 cites·5 claims
- 0886US6914160B1Oxytocin inhibitorsPFIZER·Filed 2003·Granted Jul 5, 2005·32 cites·13 claims
- 0985US8071581B2Triazolopyridazine protein kinase modulatorsSMITH CHRISTOPHER RONALD·Filed 2007·Granted Dec 6, 2011·15 cites·2 claims
- 1084US11479551B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Oct 25, 2022·1 cites·30 claims
- 1183US2023295171A1Fused heteroaromatic pyrrolidinonesCALITHERA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1282US11548888B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jan 10, 2023·1 cites·9 claims
- 1382US2024101553A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1479US9402841B2Pyridinyl and fused pyridinyl triazolone derivativesTAKEDA PHARMACEUTICALS CO·Filed 2014·Granted Aug 2, 2016·1 cites·36 claims
- 1578US9108970B2Fused heteroaromatic pyrrolidinonesTAKEDA PHARMACEUTICAL·Filed 2013·Granted Aug 18, 2015·2 cites·31 claims
- 1678US2023373999A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1777US12304915B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted May 20, 2025·0 cites·81 claims
- 1877US2024309020A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1975US9801872B2Pyridinyl and fused pyridinyl triazolone derivativesTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Oct 31, 2017·1 cites·33 claims
- 2075US9181255B2Fused heteroaromatic pyrrolidinones as SYK inhibitorsARIKAWA YASUYOSHI·Filed 2010·Granted Nov 10, 2015·2 cites·28 claims
- 2175US2025270220A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2272US2023054883A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2371US6124343ASubstituted phenyl compounds with a substituent having a thienyl ringRHONE POULENC RORER LTD·Filed 1997·Granted Sep 26, 2000·12 cites·19 claims
- 2471US2019224190A1Pyridinyl and fused pyridinyl triazolone derivativesTAKEDA PHARMACEUTICALS CO·Filed 2019·Application pending·0 cites
- 2570US6211234B1Substituted phenyl compoundsRHONE POULENC RORER LTD·Filed 1994·Granted Apr 3, 2001·26 cites·20 claims
- 2670US2025388606A1Azaquinazoline pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2768US12398154B2Azaquinazoline pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Aug 26, 2025·0 cites·49 claims
- 2868US11492351B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Nov 8, 2022·0 cites·27 claims
- 2968US2020262837A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3068US2022306634A1Fused heteroaromatic pyrrolidinonesCALITHERA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3167US11702418B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jul 18, 2023·0 cites·72 claims
- 3267US10307414B2Pyridinyl and fused pyridinyl triazolone derivativesTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Jun 4, 2019·0 cites·11 claims
- 3367US9365566B2Cinnoline derivativesTAKEDA PHARMACEUTICAL·Filed 2013·Granted Jun 14, 2016·1 cites·16 claims
- 3467US2024391882A1Substituted QuinoxalinesMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3566US7875615B2Substituted triazole derivatives as oxytocin antagonistsPFIZER·Filed 2009·Granted Jan 25, 2011·0 cites·19 claims
- 3666US2025382290A1Salts of sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3764US8507489B2Bicyclic triazoles as protein kinase modulatorsBOUNAUD PIERRE-YVES·Filed 2007·Granted Aug 13, 2013·1 cites·10 claims
- 3864US2025368649A1Tetrahydropyridopyrimidine pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3964US2024025907A1QUINAZOLINE PAN-KRas INHIBITORSMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4063US7291640B2Substituted triazole derivatives as oxytocin antagonistsPFIZER·Filed 2004·Granted Nov 6, 2007·1 cites·25 claims
- 4163US2024270719A1Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrileMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4263US2018141951A1Fused heteroaromatic pyrrolidinonesTAKEDA PHARMACEUTICALS CO·Filed 2017·Application pending·0 cites
- 4360US7649003B2Substituted triazole derivatives as oxytocin antagonistsPFIZER·Filed 2007·Granted Jan 19, 2010·0 cites·24 claims
- 4459US2024228510A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4559US2024368153A1Aminopyridine-based MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4659US2025059182A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4759US2020308170A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4857US2015336964A1Fused heteroaromatic pyrrolidinonesTAKEDA PHARMACEUTICAL·Filed 2015·Application pending·0 cites
- 4957US2024208912A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5055US2023312482A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Christopher Ronald Smith files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →